During the last session, Better Therapeutics Inc. (NASDAQ:BTTX)’s traded shares were 2.11 million. At the end of the trading day, the stock’s price was $1.83, reflecting an intraday loss of -2.14% or -$0.04. The 52-week high for the BTTX share is $29.40, that puts it down -1506.56 from that peak though still a striking 50.27% gain since the share price plummeted to a 52-week low of $0.91. The company’s market capitalization is $53.73M, and the average intraday trading volume over the past 10 days was 33.58 million shares, and the average trade volume was 5.68 million shares over the past three months.
Better Therapeutics Inc. (BTTX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. BTTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.35.
Better Therapeutics Inc. (NASDAQ:BTTX) trade information
Better Therapeutics Inc. (BTTX) registered a -2.14% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.14% in intraday trading to $1.83 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -21.79%, and it has moved by 21.19% in 30 days. Based on these gigs, the overall price performance for the year is -81.45%. The short interest in Better Therapeutics Inc. (NASDAQ:BTTX) is 0.23 million shares and it means that shorts have 6.44 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.00, which implies an increase of 89.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $21.00 respectively. As a result, BTTX is trading at a discount of -1047.54% off the target high and -719.67% off the low.
Better Therapeutics Inc. (BTTX) estimates and forecasts
Statistics show that Better Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Better Therapeutics Inc. (BTTX) shares have gone down -81.95% during the last six months, with a year-to-date growth rate more than the industry average at 35.37% against 9.70.
Better Therapeutics Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Better Therapeutics Inc. (NASDAQ:BTTX)’s Major holders
Better Therapeutics Inc. insiders own 65.85% of total outstanding shares while institutional holders control 21.51%, with the float percentage being 63.00%. Farallon Capital Management Llc is the largest shareholder of the company, while 23 institutions own stock in it. As of Dec 30, 2021, the company held over 1.35 million shares (or 5.72% of all shares), a total value of $6.28 million in shares.
The next largest institutional holding, with 0.97 million shares, is of Sectoral Asset Management, Inc.’s that is approximately 4.13% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $4.53 million.
Also, the Mutual Funds coming in first place with the largest holdings of Better Therapeutics Inc. (BTTX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.16 million shares. This amounts to just over 0.68 percent of the company’s overall shares, with a $0.75 million market value. The same data shows that the other fund manager holds slightly less at 32412.0, or about 0.14% of the stock, which is worth about $0.15 million.